Monarch Casinos & Resorts (MCRI) will release its fourth-quarter financial results after Wednesday's market close, with analysts projecting modest revenue growth but heightened scrutiny on its high-end gaming segment performance.
Bunge Global SA (NYSE:BG) is set to release its quarterly earnings Wednesday morning, with investors keen to see if the agribusiness leader can sustain its momentum amid shifting commodity markets and analyst skepticism.
Fox Corporation (NASDAQ: FOXA) is scheduled to release its fourth-quarter financial results Wednesday morning, with analysts anticipating steady revenue but slower growth compared to last year's surge.
Medical device giant Boston Scientific (BSX) is scheduled to release its fourth-quarter financial results before market open on Wednesday, with Wall Street anticipating continued strong revenue growth and another potential earnings beat.
Central Garden & Pet (CENT) is scheduled to release its fourth-quarter financial results after Wednesday's market close, with Wall Street anticipating a year-over-year revenue decline. The report comes as the broader household products sector shows investor optimism.
The fast-food giant prepares to release its quarterly results as analysts project moderated growth and investors weigh recent performance against sector peers.
CDW Corporation is set to report its fourth-quarter earnings before the market opens on Wednesday. Analysts project modest revenue growth, but the company's recent performance and broader sector trends suggest a cautious outlook.
Healthcare distribution giant Cencora (COR) is set to report quarterly earnings before Wednesday's market open. Analysts project steady revenue growth, but investor focus will be on guidance amid mixed performances from sector peers.
Industrial manufacturer IDEX (IEX) is set to release its quarterly results Wednesday morning, with Wall Street anticipating a slight revenue increase. The report comes amid a broader rally in fluid and gas handling stocks.
All eyes are on Flex (NASDAQ: FLEX) as it prepares to release its fourth-quarter earnings before the market opens on Wednesday. The contract manufacturing leader has consistently outperformed Wall Street's revenue expectations, but can it do so again in a challenging macro environment?
Nurix Therapeutics, a clinical-stage biopharma company, is gaining attention for its novel protein degradation platform. With strong early data for its lead drug, key regulatory designations, and strategic partnerships with industry giants, the company is positioning itself to address unmet needs in multi-billion dollar oncology markets.
New late-breaking data for Nektar Therapeutics' lead drug candidate, rezpegaldesleukin, suggests systemic anti-inflammatory benefits in patients with comorbid asthma, potentially expanding its market reach and strengthening the investment case for the biopharma firm.
As TTM Technologies prepares to release its quarterly results, analysts anticipate sustained revenue growth and robust performance in the competitive PCB manufacturing sector.
French biotech Abivax sees renewed investor interest following strong Phase 3 data for its oral therapy obefazimod in hard-to-treat ulcerative colitis, with analysts pointing to a clear path to regulatory approval and significant market potential.
Despite near-term pressures in China and IP markets, Synopsys's robust recurring revenue, strategic Ansys acquisition, and pivotal role in AI-driven chip design are building a compelling case for investor confidence, backed by strong margin expansion and cash flow projections.
Cronos Group's stock has rallied on renewed optimism for U.S. cannabis reform. We examine the regulatory shift, strategic positioning, and long-term potential driving investor sentiment.
Amid market volatility, a detailed analysis circulating among value investors makes a case for Kimberly-Clark Corporation. The thesis highlights the household products maker's resilient business model, technical support levels, and a valuation disconnect that could signal a compelling entry point for long-term portfolios.
Venture Global LNG, a polarizing leader in U.S. gas export infrastructure, trades at a deep discount despite record operational performance. This analysis explores the bull case for the stock, which hinges on resolving multibillion-dollar legal disputes and capitalizing on soaring global LNG demand.
The NAND flash memory specialist's stock skyrocketed last month, propelled by surging prices and blockbuster earnings that smashed Wall Street estimates, highlighting its pivotal role in the AI infrastructure build-out.
Beyond its commercial applications, Iridium Communications Inc.'s (IRDM) resilient satellite constellation is being viewed as a critical asset for modern defense architectures, driving renewed investor interest despite recent stock volatility.
